Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Published byArlene Cobb Modified over 6 years ago

Similar presentations

Presentation on theme: "Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled."— Presentation transcript:

1 Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial  Pascal Demoly, MD, PhD, Waltraud Emminger, MD, Dorte Rehm, PhD, Vibeke Backer, MD, Lene Tommerup, MSc, Jörg Kleine-Tebbe, MD  Journal of Allergy and Clinical Immunology  Volume 137, Issue 2, Pages e8 (February 2016) DOI: /j.jaci Copyright © 2015 The Authors Terms and Conditions

2 Fig 1 Overall trial design. Subjects were treated for approximately 12 months. The subjects filled in an electronic diary during 1 week after each visit and daily during the last 8 weeks of treatment (efficacy assessment period). Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

3 Fig 2 Subject disposition showing number of screened, randomized, and completed subjects, as well as reasons for discontinuations. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

4 Fig 3 Adjusted means of the TCRS and overall RQLQ(s) score over time for the 3 treatment groups (FAS). Error bars represent pairwise comparisons between each of the active dose and placebo groups. Asterisks designate statistically significant differences from placebo. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

5 Fig 4 Individual components of the AR symptom and RQLQ(S) scores in the efficacy assessment period. Scores are shown as adjusted means. Asterisks designate statistically significant differences from placebo. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

Download ppt "Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled."

Similar presentations

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial  Peter Bager, PhD, John Arnved, MD, Steen.

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial  Peter Bager, PhD, John Arnved, MD, Steen.
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Pharmacologic rationale for treating allergic and nonallergic rhinitis

Pharmacologic rationale for treating allergic and nonallergic rhinitis
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,

Similar presentations

Ads by Google